Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Similars in SciELO
Share
Gaceta médica de México
On-line version ISSN 2696-1288Print version ISSN 0016-3813
Abstract
MARTINEZ-RAMIREZ, Daniel et al. Factors associated with cognitive impairment in a Mexican multicenter Parkinson’s disease cohort: a cross-sectional comparative study. Gac. Méd. Méx [online]. 2019, vol.155, n.6, pp.602-607. Epub Oct 25, 2021. ISSN 2696-1288. https://doi.org/10.24875/gmm.19005389.
Introduction:
Cognitive impairment is common in Parkinsons disease and represents a risk for dementia. Identifying associated factors will help implement early interventions and study its progression.
Objective:
To identify factors associated with cognitive impairment.
Method:
Cross-sectional study of 306 subjects with Parkinsons disease who were assessed for 12 months. Demographics and clinical variables were analyzed as explanatory variables, and cognitive impairment as outcome variable. Significant variables were used to construct a cognitive impairment predictive model.
Results:
Cognitive impairment was reported in 43.8%. Female gender (p = 0.001, odds ratio [OR] = 1.77), age at diagnosis (p < 0.001, mean deviation [MD] = 5.7), level of education (p < 0.001, MD = −2.9), disease duration (p = 0.003, MD = 1.7), MDS-UPDRS part III score (p < 0.001, MD = 9.7), presence of anxiety (p = 0.007, OR = 2.11), hallucinations (p = 0.029, OR = 2.27) and freezing of gait (p = 0.048, OR = 1.91) were predictors for cognitive impairment. The use of type B monoamine oxidase inhibitors was associated with less cognitive impairment (p = 0.001).
Conclusions:
Predictive factors that were consistent with those previously reported were identified. Prospective studies are required in order to clarify the effect of type B monoamine oxidase inhibitors on cognition.
Keywords : Cognitive impairment; Non-motor symptoms; Parkinsons disease; Monoamine oxidase inhibitors.